The phase 2 BELIEVE trial — published in Nature Medicine and presented at the ADA 2026 Scientific Sessions this week — confirmed something the GLP-1 muscle-loss debate has needed for years: pair semaglutide with an agent that protects muscle, and almost all the weight you lose comes off as fat. The combination hit 22.1% body-weight loss with 92.8% of it from fat mass. For anyone on a GLP-1 worried about lean-mass loss, this is the cleanest body-composition signal yet.
What BELIEVE Found
BELIEVE was a double-blind, placebo-controlled phase 2 trial of 507 adults with obesity across 26 centers in the US, Australia, and New Zealand (Heymsfield et al., Nature Medicine, 2026; PMID 41772149). Participants ran 72 weeks on one of three arms: bimagrumab alone, semaglutide 2.4 mg alone, or the two combined.
The numbers separated the arms cleanly. Combination therapy produced 22.1% body-weight loss, versus 15.7% on semaglutide alone and 10.8% on bimagrumab alone. The headline is the quality of that loss: 92.8% of combination weight loss came from fat mass, with total fat mass down 45.7% and visceral adipose tissue down 58.2% (versus 27.8% and 35.8% on semaglutide alone).
Lean mass is where the trial earns its name. Semaglutide alone cut lean mass by 7.4%. Bimagrumab alone increased lean mass by 2.5%. The combination held lean-mass loss to just 2.9% — roughly a third of what semaglutide did on its own.
Bimagrumab is a first-in-class monoclonal antibody that blocks activin type II receptors, releasing the brake that myostatin and activin A put on muscle growth. Semaglutide drives intake down centrally; bimagrumab keeps the muscle on while the fat comes off. The mechanism is the point — it confirms that GLP-1 lean-mass loss is a modifiable problem, not an inevitable tax on weight loss.
What This Means for You
Bimagrumab itself is not buyable — it is an investigational IV antibody, not a peptide you can source, and it is not approved for weight loss. So the practical takeaway is not "find bimagrumab." It is what the trial proves: the muscle you lose on a GLP-1 is largely preventable, and the lever is anything that defends the GH/IGF-1 or myostatin/activin axis while you cut.
That is exactly the gap the muscle-preservation peptide stack targets. The grey-market tools people layer onto a semaglutide or tirzepatide cut chase the same body-composition outcome BELIEVE demonstrated:
- Cagrilintide — the amylin analog tested with semaglutide in the REDEFINE 1 phase 3 trial (20.4% body-weight loss at 68 weeks), where trial data described a more favorable fat-to-lean ratio than semaglutide alone. It is the closest approved-pathway analog to the BELIEVE concept.
- Tesamorelin + ipamorelin — a GHRH+GHRP stack that works through the GH/IGF-1 axis, independent of the GLP-1 pathway. Trial-reported GHRH+GHRP outcomes include preserved or increased lean muscle cross-sectional area.
- MK-677 — an oral 24-hour ghrelin-receptor agonist that raises GH and IGF-1; the Nass 2008 trial (Annals of Internal Medicine) reported a 1.6 kg fat-free-mass gain over 12 months in older adults.
None of these is bimagrumab, and none is a shortcut around the basics — BELIEVE participants were not on the kind of high-protein, resistance-training protocol that does most of the muscle-preservation work in the real world. But the trial settles the underlying question: protect muscle while you lose fat, and the scale's verdict gets a lot better.
